TipRanks
Advertisement
Advertisement

DE:6A3A Stock Latest News

Analyst Matt Phipps Reiterates Buy on Autolus, Citing Robust Oncology Growth and Long‑Term Upside from Emerging Autoimmune Pipeline
RatingsAnalyst Matt Phipps Reiterates Buy on Autolus, Citing Robust Oncology Growth and Long‑Term Upside from Emerging Autoimmune Pipeline
8d ago
AUTL
Autolus Therapeutics management to meet virtually with William Blair
PremiumThe Fly
Autolus Therapeutics management to meet virtually with William Blair
10d ago
AUTL
Autolus Therapeutics files to sell 3.5M American Depositary Shares for holders
PremiumThe Fly
Autolus Therapeutics files to sell 3.5M American Depositary Shares for holders
20d ago
AUTL
Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel
PremiumThe Fly
Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel
24d ago
AUTL
Autolus Therapeutics Earnings Call Highlights Growth Momentum
PremiumCompany Announcements
Autolus Therapeutics Earnings Call Highlights Growth Momentum
1M ago
AUTL
Gil Blum Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target on Margin Gains and Strong Aucatzyl Trajectory
PremiumRatingsGil Blum Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target on Margin Gains and Strong Aucatzyl Trajectory
2M ago
AUTL
Autolus Lifts 2026 Guidance as AUCATZYL Sales Surge
Premium
Company Announcements
Autolus Lifts 2026 Guidance as AUCATZYL Sales Surge
2M ago
8K
AUTL
Autolus Therapeutics raises FY26 revenue view to $140M-$150M from $120M-$135M
Premium
The Fly
Autolus Therapeutics raises FY26 revenue view to $140M-$150M from $120M-$135M
2M ago
AUTL
Autolus Therapeutics reports Q2 EPS (15c), consensus (19c)
PremiumThe Fly
Autolus Therapeutics reports Q2 EPS (15c), consensus (19c)
2M ago
AUTL
AUTL Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
AUTL Upcoming Earnings Report: What to Expect?
2M ago
AUTL
Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Outperforms and Non-Dilutive Financing Extends Runway; $10 Price Target Maintained
PremiumRatings
Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Outperforms and Non-Dilutive Financing Extends Runway; $10 Price Target Maintained
2M ago
AUTL
Autolus Raises AUCATZYL Outlook, Secures New Credit Facility
PremiumCompany Announcements
Autolus Raises AUCATZYL Outlook, Secures New Credit Facility
2M ago
8K
AUTL
Autolus Therapeutics reports preliminary Q2 revenue $45M, consensus $29.86M
PremiumThe FlyAutolus Therapeutics reports preliminary Q2 revenue $45M, consensus $29.86M
2M ago
AUTL
Autolus Secures New $250 Million Financing and Warrants
Premium
Company Announcements
Autolus Secures New $250 Million Financing and Warrants
2M ago
8K
AUTL
Autolus shareholders approve 2025 accounts and board slate
Premium
Company Announcements
Autolus shareholders approve 2025 accounts and board slate
3M ago
8K
AUTL
Autolus Schedules 2026 AGM and Engages ADS Holders
PremiumCompany Announcements
Autolus Schedules 2026 AGM and Engages ADS Holders
4M ago
8K
AUTL
Autolus Therapeutics Signals Turning Point in Earnings
PremiumCompany Announcements
Autolus Therapeutics Signals Turning Point in Earnings
5M ago
AUTL
Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Momentum Builds and Pipeline Advances; $10 Price Target Maintained
PremiumRatings
Autolus Therapeutics: Buy Rating Reiterated as Aucatzyl Momentum Builds and Pipeline Advances; $10 Price Target Maintained
5M ago
AUTL
Matt Phipps Reiterates Buy on Autolus as Aucatzyl’s Profitability Inflects and Blockbuster Potential Builds on Expanding Indications
PremiumRatings
Matt Phipps Reiterates Buy on Autolus as Aucatzyl’s Profitability Inflects and Blockbuster Potential Builds on Expanding Indications
5M ago
AUTL
Autolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright
PremiumThe FlyAutolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright
5M ago
AUTL
Autolus Therapeutics reports Q1 EPS (27c), consensus (26c)
Premium
The Fly
Autolus Therapeutics reports Q1 EPS (27c), consensus (26c)
5M ago
AUTL
Autolus Therapeutics backs FY26 revenue view $120M-$135M, consensus $129.39M
Premium
The Fly
Autolus Therapeutics backs FY26 revenue view $120M-$135M, consensus $129.39M
5M ago
AUTL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >